Keros Therapeutics, Inc.

KROS · Health care (pharmaceutical preparations) · 10 years of annual accounts filed with the SEC · latest fiscal year ended 2025-12-31

Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›

Keros Therapeutics, Inc. reported revenue of $244.1 million in fiscal 2025. On the accounting screens, it passes 2 of 2 Piotroski tests and its Altman Z'' of 11.55 is in the safe zone; 1 of the six cross-checks between its statements fires.

Revenue, fiscal 2025 244.1M

Operating margin 27.7% gross margin —

Return on invested capital —

Free cash flow after stock pay 77.3M 31.7% of revenue

Net debt ÷ EBITDA — net debt —

Piotroski F-score 2/2 tests of improvement passed

Share counts are in today's shares. The SEC's filings restate only recent years after a split, so these jumps were read as splits and the older years scaled to match — otherwise per-share figures would compare different units: 1-for-2 before fiscal 2025; 10-for-1 before fiscal 2020.

Is it growing?

Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.

RevenueOperating income

Compound growth a year
	3 yrs	5 yrs	9 yrs
Revenue	+309.7%	—	—
Shares	+0.4%	+8.4%	—

Falling shares are buybacks: each remaining share owns more of the company.

Does it earn more than its capital costs?

Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.

    GrossOperatingNetFree cash flow
    
  

Return on invested capital

Return on invested capital Cost of capital today · 10.2%

Economic profit

Needs a cost of capital, which comes from the valuation below.

Return on equity: 28.7%
Return on assets: 25.7%
Asset turnover: 0.72×
Research & development: 53.1% of revenue
Overheads (SG&A): 19.2% of revenue

Is the profit cash, and where does the cash go?

Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.

Net incomeFree cash flowAfter stock-based pay

Per share

    Earnings per shareFree cash flow per shareDividend per share
    
  

Shares outstanding

Diluted shares

How strong is the balance sheet?

Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.

Net debt ÷ EBITDA: —
Interest coverage: — operating income ÷ interest
Current ratio: 15.45 current assets ÷ current liabilities
Cash conversion cycle: — collects in 5d

Three classic screens of the accounts

Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.

Piotroski F-score

Is the business improving? Nine yes-or-no tests, this year against last.

2of 2 tests passed

ProfitableReturn on assets above zero — not reported no data
Cash from operationsOperating cash flow above zero passed
Profitability improvedReturn on assets higher than a year before — not reported no data
Profit backed by cashOperating cash flow above net income (low accruals) passed
Less long-term debtLong-term debt as a share of assets fell — not reported no data
More liquidCurrent ratio higher than a year before — not reported no data
No new sharesShare count did not grow — not reported no data
Better gross marginGross margin higher than a year before — not reported no data
Sells more per assetAsset turnover higher than a year before — not reported no data

Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.

Altman Z''-score

Does the balance sheet look like those of companies that went bankrupt?

11.55safe zone

Working capital ÷ assets 0.87 × 6.56+5.73
Retained earnings ÷ assets -1.43 × 3.26-4.65
Operating income ÷ assets 0.20 × 6.72+1.34
Equity ÷ liabilities 8.69 × 1.05+9.12

Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.

Beneish M-score

Do the accounts resemble those of companies that manipulated their earnings?

The accounts lack too many of the lines it needs.

Where the statements disagree

Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.

The effective tax rate is 5.3%.

Benign

A favourable geographic mix, or legitimate tax credits.

Worrying

Not sustainable; projecting it forward inflates the valuation.

What is it worth, under which assumptions?

A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.

Revenue

Starting revenue

M $

revenue of fiscal 2025

Growth in year one

revenue grew +3910.2% a year over the last 2 years; it fades to the terminal rate by the last year

Years until it settles

yrs

ten years for growth to fade to the terminal rate

Cash from each sale

Free cash flow margin today

free cash flow to the firm after stock-based pay ÷ revenue, last 1 fiscal years together

Margin in the last year

the margin in year ten; by default the business keeps today's

Count stock-based pay as a costIt is paid in shares instead of cash, and shareholders bear it through dilution. Most free cash flow figures leave it out.

The long run

Growth after that, forever

growth forever after year ten, below the risk-free rate: no company outgrows the economy forever

The discount rate

Risk-free rate

10-year US Treasury par yield (U.S. Treasury), 2026-09-25

Beta

not measured on this public page, which uses only public filings: 1.0 assumes it moves like the market. Sign in to measure it from prices

Equity risk premium

the extra return demanded for holding shares; it cannot be measured, and 4–6% is the common range

Cost of debt, before tax

no interest line: the risk-free rate + 1.5 points

Tax rate

effective rate in the last fiscal year, 5.3%, kept within 0–35%

The price

Share price

Type the price you see at your broker. It is used only for the reverse questions: what that price implies.

Back to the defaults

SEC from the filings Treasury the 10-year yield measured from prices assumption cannot be measured yours you changed it

Value per share, with these assumptions $30.02 discounted at 10.2% a year · 56% of it from after year 10

$22.6880% of 5,000 simulations$40.68

Cautious $19.04 21.0% growth · 12.3% margin · 11.2% discount · 2.0% forever

Your assumptions $30.02 25.0% growth · 14.4% margin · 10.2% discount · 2.5% forever

Generous $49.30 29.0% growth · 16.6% margin · 9.2% discount · 3.0% forever

Type a share price on the left to ask the reverse questions: what growth, what margin or what discount rate that price implies.

What the value implies, in the usual multiples

	At this model's value
Price ÷ earnings	13.1×
Enterprise value ÷ EBITDA	16.5×
Enterprise value ÷ revenue	4.7×
Free cash flow yield	6.8%

From cash flows to a value per share

10 years of cash flow, today500.8M

Everything after, today635.6M

The whole business1.1B

Minus net debt-0

What belongs to shareholders1.1B

Divided among 37.9M shares: $30.02 each.

The projection next to its history

Reported free cash flow after stock pay, then the model's. A projection that looks nothing like the past needs a reason.

ReportedProjected

Year by year

	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Revenue	305.1M	373.7M	448.5M	526.9M	606.0M	681.7M	749.9M	806.1M	846.5M	867.6M
Growth	25.0%	22.5%	20.0%	17.5%	15.0%	12.5%	10.0%	7.5%	5.0%	2.5%
Cash margin	14.4%	14.4%	14.4%	14.4%	14.4%	14.4%	14.4%	14.4%	14.4%	14.4%
Free cash flow	44.1M	54.0M	64.8M	76.1M	87.5M	98.4M	108.3M	116.4M	122.2M	125.3M
Worth today	40.0M	44.5M	48.4M	51.6M	53.9M	55.1M	55.0M	53.6M	51.1M	47.6M

If the least-known inputs move

Value per share as two inputs change at a time. Neighbouring cells that differ a lot are the conclusion: the value depends on numbers nobody knows to a point.

The discount rate and growth forever

discount ↓ · forever →	1.5%	2.0%	2.5%	3.0%	3.5%
9.2%	31	33	35	38	40
9.7%	29	31	32	34	37
10.2%	27	28	30	32	34
10.7%	25	27	28	29	31
11.2%	24	25	26	27	29

Year-one growth and the final margin

margin ↓ · growth →	21.0%	23.0%	25.0%	27.0%	29.0%
11.6%	22	23	25	27	29
13.0%	24	26	28	30	32
14.4%	26	28	30	32	35
15.9%	28	30	32	35	38
17.3%	30	32	35	38	41

All the inputs moving at once

5,000 valuations, each with growth, final margin, discount rate and growth forever drawn at random around the values on the left (spreads of 3.0%, 2.2%, 1.0% and 0.5%). Not a probability — the spreads are assumptions too — but an honest picture of how wide the answer is.

10th percentile$22.68

Median$30.05

90th percentile$40.68

Half of the simulations land between $25.83 and $35.04; one in ten below $22.68, one in ten above $40.68.

Does the long run make sense?

6.8×The terminal value prices the business in year 10 at 6.8 times that year's EBITDA.
6%To grow 2.5% forever while reinvesting 45% of its after-tax operating profit, the business must earn 6% on the new capital.
56%of the value comes from after year 10. The more of it, the more the answer depends on the part nobody can see.

The discount rate, taken apart

What shareholders demand (CAPM): 5.17% risk-free + 1.00 beta × 5.0% premium = 10.17%.
What lenders charge, after the tax saving on interest: 6.67% × (1 − 5.3%) = 6.32%.
Weighted by how much of each the company uses (book value (no price given)): 10.17%, the rate every future cash flow is discounted at.

What it has filed lately

The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.

Shares 2026-09-10

Registering new shares

Event 2026-09-08

Published other information

Event 2026-08-03

Published information for investors

Published information for investors

Event 2026-07-22

Changed a director or officer

Event 2026-06-25

Changed a director or officer; published information for investors

Estimatein 38d

Results for the period ending 2026-09-29

What its own directors and officers did

Every Form 4 filed in the last twelve months, read line by line: 6 filings by 5 people. Open-market purchases and sales are counted apart from awards, option exercises and shares withheld for taxes.

Bought on the open market$20,8802 purchase(s) by 1 insider(s)

Sold on the open market$101,1364 sale(s) by 4 insider(s)

Under pre-arranged plans25%of the sales followed a 10b5-1 plan set months earlier

Other lines00 awards · 0 option exercises · 0 tax withholdings

Date	Who	What	Shares	Price	Value	Holds after
18 Aug 2026	Tanini AnnitaCorp. Controller & VP, Finance	Sold on the open market	1,224	$10.29	$12,595	45,144
18 Aug 2026	Lerner Lorena RaquelChief Scientific Officer	Sold on the open market	3,568	$10.29	$36,715	27,559
18 Aug 2026	Cho EstherChief Legal Officer	Sold on the open market	4,485	$10.29	$46,151	35,770
18 Aug 2026	Newton Charles W.Director	Sold on the open market · pre-arranged plan	551	$10.30	$5,675	12,114
17 Aug 2026	Bienaime Jean JacquesDirector	Bought on the open market	1,000	$10.27	$10,270	19,592
15 Jul 2026	Bienaime Jean JacquesDirector	Bought on the open market	1,000	$10.61	$10,610	18,592

A Form 4 says what happened, when, how many shares and at what price. It does not say why: a sale can be diversification, a tax bill or a plan fixed months earlier, and an award is pay, not a purchase. Nothing here is a reason to buy or sell anything.

Companies like this one

Same SEC industry (pharmaceutical preparations) first, then the rest of health care.

LLY ELI Lilly & Co JNJ Johnson & Johnson ABBV AbbVie Inc.MRK Merck & Co., Inc.ABT Abbott Laboratories PFE Pfizer Inc VRTX Vertex Pharmaceuticals Inc / MA BMY Bristol Myers Squibb Co

Every figure, year by year

10 fiscal years · 30 measures

	2018	2019	2020	2021	2022	2023	2024	2025	2025	2025
Size
Revenue	—	10.0M	0	20.1M	0	151,000	3.5M	—	—	244.1M
Revenue growth	—	—	—	—	—	—	+2251.0%	—	—	—
Operating income	—	-10.6M	-46.7M	-56.4M	-114.8M	-169.9M	-210.8M	—	—	67.6M
Net income	—	-12.3M	-45.4M	-58.7M	-104.7M	-153.0M	-187.4M	—	—	87.0M
Margins
Gross margin	—	—	—	—	—	—	—	—	—	—
Operating margin	—	-105.6%	—	-280.5%	—	-112543.7%	-5939.0%	—	—	27.7%
Net margin	—	-123.4%	—	-292.3%	—	-101319.2%	-5277.5%	—	—	35.7%
Free cash flow margin	—	-162.7%	—	-314.3%	—	-84087.4%	-4585.9%	—	—	43.4%
R&D ÷ revenue	—	173.8%	—	274.3%	—	89574.8%	4891.0%	—	—	53.1%
SG&A ÷ revenue	—	31.8%	—	106.1%	—	23068.9%	1148.0%	—	—	19.2%
Cash
Free cash flow	—	-16.3M	-37.2M	-63.2M	-71.3M	-127.0M	-162.8M	—	—	106.0M
Stock-based pay	—	59,000	4.1M	11.7M	18.7M	28.8M	34.9M	—	—	28.7M
Free cash flow after stock pay	—	-16.3M	-41.3M	-74.9M	-90.0M	-155.7M	-197.7M	—	—	77.3M
Free cash flow to the firm	—	-10.6M	-46.8M	-75.5M	-97.7M	-169.6M	-215.3M	—	—	63.9M
Free cash flow ÷ net income	—	1.3×	0.8×	1.1×	0.7×	0.8×	0.9×	—	—	1.2×
Capex ÷ revenue	—	2.7%	—	5.1%	—	1631.8%	54.4%	—	—	0.6%
Returns
Return on invested capital	—	—	—	—	—	—	—	—	—	—
Return on equity	—	—	-17.3%	-24.2%	-37.7%	-46.1%	-32.8%	—	—	28.7%
Return on assets	—	-112.6%	-16.8%	-23.0%	-34.1%	-41.3%	-30.4%	—	—	25.7%
Asset turnover	—	0.9×	0.0×	0.1×	0.0×	0.0×	0.0×	—	—	0.7×
Economic profit	—	—	—	—	—	—	—	—	—	—
Per share
Earnings per share	—	$-1.02	$-2.93	$-2.52	$-4.15	$-5.20	$-5.00	—	—	$2.30
Free cash flow per share	—	$-1.34	$-2.40	$-2.71	$-2.82	$-4.31	$-4.35	—	—	$2.80
Dividend per share	—	—	—	—	—	—	—	—	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—
Book value per share	—	$-1.60	$22.57	$20.29	$20.14	$20.87	$28.19	—	—	$15.51
Diluted shares	—	12.1M	15.5M	23.3M	25.2M	29.4M	37.4M	—	—	37.9M
Balance sheet
Net debt	—	—	—	—	—	—	—	—	—	—
Net debt ÷ EBITDA	—	—	—	—	—	—	—	—	—	—
Interest coverage	—	—	-7776.2×	-14093.2×	-114790.0×	—	—	—	—	—
Current ratio	—	2.0×	37.3×	21.2×	17.3×	14.2×	21.5×	—	—	15.5×
Cash conversion cycle (days)	—	—	—	—	—	—	—	—	—	—
Scores
Piotroski F-score	—	0	3	1	1	2	4	0	0	2
Altman Z''	—	-11.62	39.98	24.23	10.74	8.50	14.21	—	—	11.55
Beneish M	—	—	—	—	—	—	17.36	—	—	—

Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.